The pharmaceutical industry is expanding its attack on President Joe Biden’s plan to lower Medicare drug prices into allegations that the administration violated procedural norms in implementing the program, a tactic legal experts say will run into roadblocks but that could ultimately prevail.
The APA claims mark important additions to “the litigation saga” unfolding around drug pricing, said Margaux Hall, partner in Ropes & Gray LLP’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.